These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1098 related items for PubMed ID: 9580626

  • 1. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.
    Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, Piattoni-Kaplan M, McKenna DG, Wasicak JT, Holladay MW, Williams M, Arneric SP.
    J Pharmacol Exp Ther; 1998 May; 285(2):777-86. PubMed ID: 9580626
    [Abstract] [Full Text] [Related]

  • 2. (+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors.
    Sullivan JP, Decker MW, Brioni JD, Donnelly-Roberts D, Anderson DJ, Bannon AW, Kang CH, Adams P, Piattoni-Kaplan M, Buckley MJ.
    J Pharmacol Exp Ther; 1994 Nov; 271(2):624-31. PubMed ID: 7965777
    [Abstract] [Full Text] [Related]

  • 3. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
    Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS.
    J Pharmacol Exp Ther; 1994 Jul; 270(1):310-8. PubMed ID: 7518514
    [Abstract] [Full Text] [Related]

  • 4. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.
    Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Piattoni-Kaplan M, Campbell JE, McKenna DG, Molinari E, Hettinger AM, Garvey DS, Wasicak JT, Holladay MW, Williams M, Arneric SP.
    Neuropharmacology; 1996 Jun; 35(6):725-34. PubMed ID: 8887981
    [Abstract] [Full Text] [Related]

  • 5. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.
    Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, Piattoni-Kaplan M, Molinari E, Campbell JE, McKenna DG, Gunn DE, Lin NH, Ryther KB, He Y, Holladay MW, Wonnacott S, Williams M, Arneric SP.
    J Pharmacol Exp Ther; 1997 Oct; 283(1):235-46. PubMed ID: 9336329
    [Abstract] [Full Text] [Related]

  • 6. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.
    Gopalakrishnan M, Monteggia LM, Anderson DJ, Molinari EJ, Piattoni-Kaplan M, Donnelly-Roberts D, Arneric SP, Sullivan JP.
    J Pharmacol Exp Ther; 1996 Jan; 276(1):289-97. PubMed ID: 8558445
    [Abstract] [Full Text] [Related]

  • 7. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.
    Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ, Lynch JK, Wasicak JT, Lin NH, Arnold WH, Holladay MW, Williams M, Arneric SP.
    J Pharmacol Exp Ther; 1998 May; 285(2):787-94. PubMed ID: 9580627
    [Abstract] [Full Text] [Related]

  • 8. Evidence for nicotinic receptors potentially modulating nociceptive transmission at the level of the primary sensory neuron: studies with F11 cells.
    Puttfarcken PS, Manelli AM, Arneric SP, Donnelly-Roberts DL.
    J Neurochem; 1997 Sep; 69(3):930-8. PubMed ID: 9282914
    [Abstract] [Full Text] [Related]

  • 9. Gene targeting demonstrates that alpha4 nicotinic acetylcholine receptor subunits contribute to expression of diverse [3H]epibatidine binding sites and components of biphasic 86Rb+ efflux with high and low sensitivity to stimulation by acetylcholine.
    Marks MJ, Meinerz NM, Drago J, Collins AC.
    Neuropharmacology; 2007 Sep; 53(3):390-405. PubMed ID: 17631923
    [Abstract] [Full Text] [Related]

  • 10. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors.
    Gerzanich V, Peng X, Wang F, Wells G, Anand R, Fletcher S, Lindstrom J.
    Mol Pharmacol; 1995 Oct; 48(4):774-82. PubMed ID: 7476906
    [Abstract] [Full Text] [Related]

  • 11. Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats.
    Boyce S, Webb JK, Shepheard SL, Russell MGN, Hill RG, Rupniak NMJ.
    Pain; 2000 Apr; 85(3):443-450. PubMed ID: 10781917
    [Abstract] [Full Text] [Related]

  • 12. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains.
    Warpman U, Nordberg A.
    Neuroreport; 1995 Nov 27; 6(17):2419-23. PubMed ID: 8747166
    [Abstract] [Full Text] [Related]

  • 13. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.
    Holladay MW, Wasicak JT, Lin NH, He Y, Ryther KB, Bannon AW, Buckley MJ, Kim DJ, Decker MW, Anderson DJ, Campbell JE, Kuntzweiler TA, Donnelly-Roberts DL, Piattoni-Kaplan M, Briggs CA, Williams M, Arneric SP.
    J Med Chem; 1998 Feb 12; 41(4):407-12. PubMed ID: 9484491
    [Abstract] [Full Text] [Related]

  • 14. Interaction of the nicotinic agonist (R,S)-3-pyridyl-1-methyl-2-(3-pyridyl)-azetidine (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex.
    Zhang X, Gong ZH, Fasth KJ, Långström B, Nordberg A.
    Neurochem Int; 1998 Feb 12; 32(5-6):435-41. PubMed ID: 9676742
    [Abstract] [Full Text] [Related]

  • 15. Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity.
    Parker MJ, Beck A, Luetje CW.
    Mol Pharmacol; 1998 Dec 12; 54(6):1132-9. PubMed ID: 9855644
    [Abstract] [Full Text] [Related]

  • 16. Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain.
    Kesingland AC, Gentry CT, Panesar MS, Bowes MA, Vernier JM, Cube R, Walker K, Urban L.
    Pain; 2000 May 12; 86(1-2):113-8. PubMed ID: 10779668
    [Abstract] [Full Text] [Related]

  • 17. The heterocyclic substituted pyridine derivative (+/-)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429): a selective ligand at nicotinic acetylcholine receptors.
    Bencherif M, Schmitt JD, Bhatti BS, Crooks P, Caldwell WS, Lovette ME, Fowler K, Reeves L, Lippiello PM.
    J Pharmacol Exp Ther; 1998 Mar 12; 284(3):886-94. PubMed ID: 9495846
    [Abstract] [Full Text] [Related]

  • 18. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. III. Agonist actions of the novel alkaloid epibatidine and analysis of type II current.
    Alkondon M, Albuquerque EX.
    J Pharmacol Exp Ther; 1995 Aug 12; 274(2):771-82. PubMed ID: 7543571
    [Abstract] [Full Text] [Related]

  • 19. Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells.
    Riganti L, Matteoni C, Di Angelantonio S, Nistri A, Gaimarri A, Sparatore F, Canu-Boido C, Clementi F, Gotti C.
    Br J Pharmacol; 2005 Dec 12; 146(8):1096-109. PubMed ID: 16273122
    [Abstract] [Full Text] [Related]

  • 20. Characterization of [3H]ABT-418: a novel cholinergic channel ligand.
    Anderson DJ, Williams M, Pauly JR, Raszkiewicz JL, Campbell JE, Rotert G, Surber B, Thomas SB, Wasicak J, Arneric SP.
    J Pharmacol Exp Ther; 1995 Jun 12; 273(3):1434-41. PubMed ID: 7791118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.